paul m bisaro  zoetis  zoetis zoetiscom uses cookies to improve your experience when browsing our website by continuing to use this site you are agreeing to their use to find out more view our cookie policy agree about uszoetis at a glance vision  mission core beliefs awards  recognition history zoetis executive teamboard committees  charters board of directors contact our directors corporate governancepolicies  procedures board committees  charters board of directors contact our directors corporate compliance company locations home  about us  corporate governance  board of directors  board of directors share share on twitter share on facebook share on linkedin share on googleplusoneshare share on email print text size  prev next  board of directors paul m bisaro paul m bisaro has served as a member of the zoetis board of directors since may  mr bisaro is president and chief executive officer of impax laboratories a specialty pharmaceutical company since march   he was the executive chairman of the board of directors of allergan plc formerly actavis plc from july  to october  until june  mr bisaro served as board chairman president and chief executive officer of actavis formerly watson pharmaceuticals he was appointed president chief executive officer and a member of the board of watson pharmaceuticals in september  and later appointed chairman of the board of watson pharmaceuticals in october  prior to joining watson mr bisaro was president chief operating officer and a member of the board of barr pharmaceuticals inc a global specialty pharmaceutical company from  to  between  and  he served as general counsel of barr and from  to  he served in various additional capacities including senior vice president – strategic business development prior to joining barr mr bisaro was associated with the law firm winston  strawn and a predecessor firm bishop cook purcell and reynolds from  to  mr bisaro currently serves on the board of directors of allergan plc impax laboratories and zimmer biomet holdings inc a world leader in musculoskeletal health solutions and on the board of visitors of the catholic university of america’s columbus school of law mr bisaro holds an undergraduate degree in general studies from the university of michigan and a juris doctor from the catholic university of america in washington dc about us see zoetis at a glancemore select a country zoetiscom zoetiszocom argentina australia austria belgium french belgium dutch brazil bolivia bulgaria canada chile china colombia costa rica croatia czech republic ecuador egypt estonia finland france germany greece hungary india indonesia ireland israel italy japan latvia lithuania malaysia mexico morocco netherlands new zealand paraguay peru philippines poland portugal romania russia serbia slovakia slovenia south africa south korea spain switzerland taiwan thailand turkey ukraine united kingdom united states uruguay vietnam you are leaving the country website to access another site in the group regulatory constraints and medical practices vary from country to country consequently the information provided on the site in which you enter may not be suitable for use in your country home sitemap privacy policy cookie policy terms of use impax board of directors appoints paul m bisaro president and ceohomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq impax board of directors appoints paul m bisaro president and ceopr newswiremarch  reblogsharetweetsharehayward calif march   prnewswire  impax laboratories inc ipxltoday announced that its board of directors has appointed paul m bisaro as impaxs president and chief executive officer and a member of the companys board effective march   mr bisaro will succeed j kevin buchi who has served as interim president and chief executive officer since december of with  years of generic and branded pharmaceutical experience mr bisaro  is an accomplished global business leader who brings a successful record of leading operational execution and corporate transformation resulting in company growth he previously served as executive chairman of allergan plc formerly actavis plc president and ceo of actavis formerly watson pharmaceuticals inc and chairman of the boardwe are pleased to have paul a highly respected and accomplished leader with a strong track record of delivering superior shareholder returns and financial performance join impax as our new ceo said robert l burr chairman of impax laboratories inc following a thorough review of candidates the board determined that pauls broad experience across the specialty pharmaceutical industry and demonstrated ability to grow and transform an organization make him the right person to oversee the companys future direction on behalf of the entire board i would also like to thank kevin for his leadership in stepping into the interim ceo rolei am excited about the opportunity to lead impax to its full potential in a rapidly changing environment said mr bisaro impax has a strong reputation for its drug delivery formulation and product development capabilities we will continue to focus on developing highquality products that meet the unique needs of our patients combining our rd priorities with providing best in class customer service will provide additional value to our customers and deliver value for our shareholdersprior to joining watson in  mr bisaro was president chief operating officer and a member of the board of directors of barr pharmaceuticals inc a global specialty pharmaceutical company barr from  to  between  and  mr bisaro served as general counsel of barr and from  to  served in various additional capacities prior to joining barr he was associated with the law firm winston  strawn and a predecessor firm bishop cook purcell and reynolds from  to  he also served as a senior consultant with arthur andersen  comr bisaro currently serves on the board of directors of allergan zoetis inc and on the board of visitors of the catholic university of americas columbus school of law mr bisaro also serves on the board of zimmer biomet holdings inc but has notified the board that he will not stand for reelection as a director at the companys  annual meeting of stockholders he also served as chairman of the board of the generic pharmaceutical association gpha in  and mr bisaro received his undergraduate degree in general studies from the university of michigan and a juris doctor from catholic university of america in washington dcabout impax laboratories incimpax laboratories inc impax is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlledrelease and specialty generics in addition to the development of central nervous system disorder branded products impax markets its generic products through its impax generics division and markets its branded products through the impax specialty pharma division additionally where strategically appropriate impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies such as injectables nasal sprays inhalers patches creams and ointmentsread morefor more information visit impaxs website at wwwimpaxlabscomsafe harbor statement under the private securities litigation reform act of to the extent any statements made in this news release contain information that is not historical these statements are forwardlooking in nature and express the beliefs and expectations of management such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the companys future results performance or achievements to differ significantly from the results performance or achievements expressed or implied by such forwardlooking statements such risks and uncertainties include but are not limited to fluctuations in the companys operating results and financial condition the volatility of the market price of the companys common stock the companys ability to successfully develop and commercialize pharmaceutical products in a timely manner the impact of competition the effect of any manufacturing or quality control problems  the companys ability to manage its growth risks related to acquisitions of or investments in technologies products or businesses risks relating to goodwill and intangibles the reduction or loss of business with any significant customer the substantial portion of the companys total revenues derived from sales of a limited number of products the impact of consolidation of the companys customer base the companys ability to sustain profitability and positive cash flows the impact of any valuation allowance on the companys deferred tax assets the restrictions imposed by the companys credit facility and indenture the companys level of indebtedness and liabilities and the potential impact on cash flow available for operations the availability of additional funds in the future any delays or unanticipated expenses in connection with the operation of the companys manufacturing facilities the effect of foreign economic political legal and other risks on the companys operations abroad the uncertainty of patent litigation and other legal proceedings the increased government scrutiny on the companys agreements to settle patent litigations product development risks and the difficulty of predicting fda filings and approvals consumer acceptance and demand for new pharmaceutical products the impact of market perceptions of the company and the safety and quality of the companys products the companys determinations to discontinue the manufacture and distribution of certain products the companys ability to achieve returns on its investments in research and development activities changes to fda approval requirements the companys ability to successfully conduct clinical trials the companys reliance on third parties to conduct clinical trials and testing the companys lack of a license partner for commercialization of numient® ipx outside of the united states impact of illegal distribution and sale by third parties of counterfeits or stolen products the availability of raw materials and impact of interruptions in the companys supply chain the companys policies regarding returns rebates allowances and chargebacks the use of controlled substances in the companys products the effect of current economic conditions on the companys industry business results of operations and financial condition disruptions or failures in the companys information technology systems and network infrastructure caused by third party breaches or other events the companys reliance on alliance and collaboration agreements the companys reliance on licenses to proprietary technologies the companys dependence on certain employees the companys ability to comply with legal and regulatory requirements governing the healthcare industry the regulatory environment the effect of certain provisions in the companys government contracts the companys ability to protect its intellectual property exposure to product liability claims changes in tax regulations uncertainties involved in the preparation of the companys financial statements the companys ability to maintain an effective system of internal control over financial reporting the effect of terrorist attacks on the companys business the location of the companys manufacturing and research and development facilities near earthquake fault lines expansion of social media platforms and other risks described in the companys periodic reports filed with the securities and exchange commission  forwardlooking statements speak only as to the date on which they are made and the company undertakes no obligation to update publicly or revise any forwardlooking statement regardless of whether new information becomes available future developments occur or otherwisecontactmark donohue investor relations and corporate communications  to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesimpaxboardofdirectorsappointspaulmbisaropresidentandceohtmlreblogsharetweetsharerecently viewedyour list is emptywhat to read nextpg procter  gamble pretty good yes reallyforbesoj simpson owes millions heres why he can retire comfortably and never work again anywaymoneythe cia director just dropped some heavy hints that the us is looking into regime change in north koreabusiness insiderwhy it might be ‘dangerous’ for ibm to turn itself around professoryahoo financeglaxosmithklines new ceo prepares to trim drug pipelinereutersaetna ceo bertolini how tech plays into the future of healthcareyahoo finance videocall of the week nows the time to buy chipotleyahoo finance dudes in a car blissing out in the lincoln continentalyahoo financedemocrats herald agreement on sweeping russia sanctions billassociated presswhat its like to ship yourself overnight on cabins sleep pod bustechcrunchaetna ceo bertolini why he pays his employees to sleepyahoo finance videostocks back off from record highsyahoo financepokémon gos first realworld event was a disaster and everyone was refundedbusiness insidera former biotech executive whos living with terminal cancer wants to reset expectations about new cancer treatmentsbusiness insiderget a closer look at the tesla model  as it drives awayautoblogaetna ceo bertolini how his own accident and son’s cancer changed his journeyyahoo finance videoisraeli raid jerusalem clashes ratchet tensions higherjal this place is sacred to all  abrahamic faith traditions muslim jewish and christian and muslims fears that israel wants it for their own religious and national purposes are unfortunately well grounded tel aviv wants to wrest control of it back for israel because in jewish religious traditions the building of the rd temple will herald the beginning of the messianic age israeli prime minister knew that the optics of the metal detectors and forbidding anyone under  to worship at al aqsa would be horrific but in his characteristic hubris he just didnt give a damn through these actions he may well have lit the flames for yet another intifada then he will use this violence as the justification to tighten down the screws against palestinians even more than they are already i weep for all those dead and wounded jewish muslim and christian and those who will die and be wounded on all sides this is an absolute tragedy which could have been averted a violent response to these strictures for worshiping at al aqsa was precisely the outcome netanyahu and the israeli government wanted to happenjoin the conversation   impax board of directors appoints paul m bisaro president and ceo impax board of directors appoints paul m bisaro president and ceo industry veteran brings a successful record of operational execution driving transformation and delivering growth news provided by impax laboratories inc mar    et share this article hayward calif march   prnewswire  impax laboratories inc nasdaq ipxltoday announced that its board of directors has appointed paul m bisaro as impaxs president and chief executive officer and a member of the companys board effective march   mr bisaro will succeed j kevin buchi who has served as interim president and chief executive officer since december of  prnewsfotoimpax laboratories inc with  years of generic and branded pharmaceutical experience mr bisaro  is an accomplished global business leader who brings a successful record of leading operational execution and corporate transformation resulting in company growth he previously served as executive chairman of allergan plc formerly actavis plc president and ceo of actavis formerly watson pharmaceuticals inc and chairman of the board we are pleased to have paul a highly respected and accomplished leader with a strong track record of delivering superior shareholder returns and financial performance join impax as our new ceo said robert l burr chairman of impax laboratories inc following a thorough review of candidates the board determined that pauls broad experience across the specialty pharmaceutical industry and demonstrated ability to grow and transform an organization make him the right person to oversee the companys future direction on behalf of the entire board i would also like to thank kevin for his leadership in stepping into the interim ceo role i am excited about the opportunity to lead impax to its full potential in a rapidly changing environment said mr bisaro impax has a strong reputation for its drug delivery formulation and product development capabilities we will continue to focus on developing highquality products that meet the unique needs of our patients combining our rd priorities with providing best in class customer service will provide additional value to our customers and deliver value for our shareholders prior to joining watson in  mr bisaro was president chief operating officer and a member of the board of directors of barr pharmaceuticals inc a global specialty pharmaceutical company barr from  to  between  and  mr bisaro served as general counsel of barr and from  to  served in various additional capacities prior to joining barr he was associated with the law firm winston  strawn and a predecessor firm bishop cook purcell and reynolds from  to  he also served as a senior consultant with arthur andersen  co mr bisaro currently serves on the board of directors of allergan zoetis inc and on the board of visitors of the catholic university of americas columbus school of law mr bisaro also serves on the board of zimmer biomet holdings inc but has notified the board that he will not stand for reelection as a director at the companys  annual meeting of stockholders he also served as chairman of the board of the generic pharmaceutical association gpha in  and  mr bisaro received his undergraduate degree in general studies from the university of michigan and a juris doctor from catholic university of america in washington dc about impax laboratories incimpax laboratories inc impax is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlledrelease and specialty generics in addition to the development of central nervous system disorder branded products impax markets its generic products through its impax generics division and markets its branded products through the impax specialty pharma division additionally where strategically appropriate impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies such as injectables nasal sprays inhalers patches creams and ointments for more information visit impaxs website at wwwimpaxlabscom safe harbor statement under the private securities litigation reform act of to the extent any statements made in this news release contain information that is not historical these statements are forwardlooking in nature and express the beliefs and expectations of management such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the companys future results performance or achievements to differ significantly from the results performance or achievements expressed or implied by such forwardlooking statements such risks and uncertainties include but are not limited to fluctuations in the companys operating results and financial condition the volatility of the market price of the companys common stock the companys ability to successfully develop and commercialize pharmaceutical products in a timely manner the impact of competition the effect of any manufacturing or quality control problems  the companys ability to manage its growth risks related to acquisitions of or investments in technologies products or businesses risks relating to goodwill and intangibles the reduction or loss of business with any significant customer the substantial portion of the companys total revenues derived from sales of a limited number of products the impact of consolidation of the companys customer base the companys ability to sustain profitability and positive cash flows the impact of any valuation allowance on the companys deferred tax assets the restrictions imposed by the companys credit facility and indenture the companys level of indebtedness and liabilities and the potential impact on cash flow available for operations the availability of additional funds in the future any delays or unanticipated expenses in connection with the operation of the companys manufacturing facilities the effect of foreign economic political legal and other risks on the companys operations abroad the uncertainty of patent litigation and other legal proceedings the increased government scrutiny on the companys agreements to settle patent litigations product development risks and the difficulty of predicting fda filings and approvals consumer acceptance and demand for new pharmaceutical products the impact of market perceptions of the company and the safety and quality of the companys products the companys determinations to discontinue the manufacture and distribution of certain products the companys ability to achieve returns on its investments in research and development activities changes to fda approval requirements the companys ability to successfully conduct clinical trials the companys reliance on third parties to conduct clinical trials and testing the companys lack of a license partner for commercialization of numient® ipx outside of the united states impact of illegal distribution and sale by third parties of counterfeits or stolen products the availability of raw materials and impact of interruptions in the companys supply chain the companys policies regarding returns rebates allowances and chargebacks the use of controlled substances in the companys products the effect of current economic conditions on the companys industry business results of operations and financial condition disruptions or failures in the companys information technology systems and network infrastructure caused by third party breaches or other events the companys reliance on alliance and collaboration agreements the companys reliance on licenses to proprietary technologies the companys dependence on certain employees the companys ability to comply with legal and regulatory requirements governing the healthcare industry the regulatory environment the effect of certain provisions in the companys government contracts the companys ability to protect its intellectual property exposure to product liability claims changes in tax regulations uncertainties involved in the preparation of the companys financial statements the companys ability to maintain an effective system of internal control over financial reporting the effect of terrorist attacks on the companys business the location of the companys manufacturing and research and development facilities near earthquake fault lines expansion of social media platforms and other risks described in the companys periodic reports filed with the securities and exchange commission  forwardlooking statements speak only as to the date on which they are made and the company undertakes no obligation to update publicly or revise any forwardlooking statement regardless of whether new information becomes available future developments occur or otherwise contactmark donohueinvestor relations and corporate communications  to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesimpaxboardofdirectorsappointspaulmbisaropresidentandceohtml source impax laboratories inc related links httpwwwimpaxlabscom mar    et preview impax announces favorable ruling regarding patent validity for zomig® zolmitriptan nasal spray mar    et preview impax reports fourth quarter and full year  financial results my news release contains wide tables view fullscreen also from this source jul    et impax announces fda approval of its ab rated generic concerta® jul    et impax announces fda approval and launch of additional strengths explore more news releases in similar topics health care  hospitals medical pharmaceuticals pharmaceuticals personnel announcements you just read impax board of directors appoints paul m bisaro president and ceo news provided by impax laboratories inc mar    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search impax laboratories inc  impax board of directors appoints paul m bisaro president and ceo investor relations  media center  careers  contact homeour companyour experienceour divisionsmedia center media center media center media center press releases download library media centerpress releasesdownload librarymedia center home»media center»press releases»press release press release  back impax board of directors appoints paul m bisaro president and ceo  download this press release pdf industry veteran brings a successful record of operational execution driving transformation and delivering growth hayward calif march   prnewswire  impax laboratories inc nasdaq ipxltoday announced that its board of directors has appointed paul m bisaro as impaxs president and chief executive officer and a member of the companys board effective march   mr bisaro will succeed j kevin buchi who has served as interim president and chief executive officer since december of  with  years of generic and branded pharmaceutical experience mr bisaro  is an accomplished global business leader who brings a successful record of leading operational execution and corporate transformation resulting in company growth he previously served as executive chairman of allergan plc formerly actavis plc president and ceo of actavis formerly watson pharmaceuticals inc and chairman of the board we are pleased to have paul a highly respected and accomplished leader with a strong track record of delivering superior shareholder returns and financial performance join impax as our new ceo said robert l burr chairman of impax laboratories inc following a thorough review of candidates the board determined that pauls broad experience across the specialty pharmaceutical industry and demonstrated ability to grow and transform an organization make him the right person to oversee the companys future direction on behalf of the entire board i would also like to thank kevin for his leadership in stepping into the interim ceo role i am excited about the opportunity to lead impax to its full potential in a rapidly changing environment said mr bisaro impax has a strong reputation for its drug delivery formulation and product development capabilities we will continue to focus on developing highquality products that meet the unique needs of our patients combining our rd priorities with providing best in class customer service will provide additional value to our customers and deliver value for our shareholders prior to joining watson in  mr bisaro was president chief operating officer and a member of the board of directors of barr pharmaceuticals inc a global specialty pharmaceutical company barr from  to  between  and  mr bisaro served as general counsel of barr and from  to  served in various additional capacities prior to joining barr he was associated with the law firm winston  strawn and a predecessor firm bishop cook purcell and reynolds from  to  he also served as a senior consultant with arthur andersen  co mr bisaro currently serves on the board of directors of allergan zoetis inc and on the board of visitors of the catholic university of americas columbus school of law mr bisaro also serves on the board of zimmer biomet holdings inc but has notified the board that he will not stand for reelection as a director at the companys  annual meeting of stockholders he also served as chairman of the board of the generic pharmaceutical association gpha in  and  mr bisaro received his undergraduate degree in general studies from the university of michigan and a juris doctor from catholic university of america in washington dc about impax laboratories incimpax laboratories inc impax is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlledrelease and specialty generics in addition to the development of central nervous system disorder branded products impax markets its generic products through its impax generics division and markets its branded products through the impax specialty pharma division additionally where strategically appropriate impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies such as injectables nasal sprays inhalers patches creams and ointments for more information visit impaxs website at wwwimpaxlabscom safe harbor statement under the private securities litigation reform act of to the extent any statements made in this news release contain information that is not historical these statements are forwardlooking in nature and express the beliefs and expectations of management such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the companys future results performance or achievements to differ significantly from the results performance or achievements expressed or implied by such forwardlooking statements such risks and uncertainties include but are not limited to fluctuations in the companys operating results and financial condition the volatility of the market price of the companys common stock the companys ability to successfully develop and commercialize pharmaceutical products in a timely manner the impact of competition the effect of any manufacturing or quality control problems  the companys ability to manage its growth risks related to acquisitions of or investments in technologies products or businesses risks relating to goodwill and intangibles the reduction or loss of business with any significant customer the substantial portion of the companys total revenues derived from sales of a limited number of products the impact of consolidation of the companys customer base the companys ability to sustain profitability and positive cash flows the impact of any valuation allowance on the companys deferred tax assets the restrictions imposed by the companys credit facility and indenture the companys level of indebtedness and liabilities and the potential impact on cash flow available for operations the availability of additional funds in the future any delays or unanticipated expenses in connection with the operation of the companys manufacturing facilities the effect of foreign economic political legal and other risks on the companys operations abroad the uncertainty of patent litigation and other legal proceedings the increased government scrutiny on the companys agreements to settle patent litigations product development risks and the difficulty of predicting fda filings and approvals consumer acceptance and demand for new pharmaceutical products the impact of market perceptions of the company and the safety and quality of the companys products the companys determinations to discontinue the manufacture and distribution of certain products the companys ability to achieve returns on its investments in research and development activities changes to fda approval requirements the companys ability to successfully conduct clinical trials the companys reliance on third parties to conduct clinical trials and testing the companys lack of a license partner for commercialization of numient® ipx outside of the united states impact of illegal distribution and sale by third parties of counterfeits or stolen products the availability of raw materials and impact of interruptions in the companys supply chain the companys policies regarding returns rebates allowances and chargebacks the use of controlled substances in the companys products the effect of current economic conditions on the companys industry business results of operations and financial condition disruptions or failures in the companys information technology systems and network infrastructure caused by third party breaches or other events the companys reliance on alliance and collaboration agreements the companys reliance on licenses to proprietary technologies the companys dependence on certain employees the companys ability to comply with legal and regulatory requirements governing the healthcare industry the regulatory environment the effect of certain provisions in the companys government contracts the companys ability to protect its intellectual property exposure to product liability claims changes in tax regulations uncertainties involved in the preparation of the companys financial statements the companys ability to maintain an effective system of internal control over financial reporting the effect of terrorist attacks on the companys business the location of the companys manufacturing and research and development facilities near earthquake fault lines expansion of social media platforms and other risks described in the companys periodic reports filed with the securities and exchange commission  forwardlooking statements speak only as to the date on which they are made and the company undertakes no obligation to update publicly or revise any forwardlooking statement regardless of whether new information becomes available future developments occur or otherwise contactmark donohueinvestor relations and corporate communications  to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesimpaxboardofdirectorsappointspaulmbisaropresidentandceohtml source impax laboratories inc related links products and pipeline leadership contact investor toolkit email page rss feeds email alerts copyright   impax laboratories inc all rights reserved sitemap  legal and copyright disclaimer name first name is required email email is required comments enter text   enter the code shown above  invalid powered by q inc  zoetis appoints paul m bisaro to board of directors  press releases  zoetis skip to main content skip to navigation search form search select a country zoetiscom argentina australia austria belgium bolivia brazil bulgaria canada chile china colombia costa rica croatia czech republic ecuador egypt estonia finland france germany greece hungary india indonesia ireland israel italy japan latvia lithuania malaysia mexico morocco netherlands new zealand paraguay peru philippines poland portugal romania russia serbia slovakia slovenia south africa south korea spain switzerland taiwan thailand turkey ukraine united kingdom united states uruguay venezuela vietnam header menu investors news  media careers contact us ☰ text size print share           search form search choose country argentina australia austria belgium bolivia brazil bulgaria canada chile china colombia costa rica croatia czech republic ecuador egypt estonia finland france germany greece hungary india indonesia ireland israel italy japan latvia lithuania malaysia mexico morocco netherlands new zealand paraguay peru philippines poland portugal romania russia serbia slovakia slovenia south africa south korea spain switzerland taiwan thailand turkey ukraine united kingdom united states uruguay venezuela vietnam argentina australia austria belgium bolivia brazil bulgaria canada chile china colombia costa rica croatia czech republic ecuador egypt estonia finland france germany greece hungary india indonesia ireland israel italy japan latvia lithuania malaysia mexico morocco netherlands new zealand paraguay peru philippines poland portugal romania russia serbia slovakia slovenia south africa south korea spain switzerland taiwan thailand turkey ukraine united kingdom united states uruguay venezuela vietnam login home news zoetis appoints paul m bisaro to board of directors news  media press releasescompanion animals farm animals corporate products  services media statements in the news feature stories photo gallery video gallery media kit media contacts press releasesmost recent companion animals farm animals corporate financial products  services              enter your keywords advanced search zoetis appoints paul m bisaro to board of directors category corporate investors leadership people monday april    am edt dateline florham park nj emailpdfprintrss public company information nysezts forwardlooking information and factors that may affect future results florham park njbusiness wirezoetis inc nysezts today announced that its board of directors has appointed paul m bisaro executive chairman of actavis plc to the company’s board of directors mr bisaro’s term will begin immediately following the company’s  annual meeting of shareholders which is scheduled for may   with the addition of mr bisaro the zoetis board will expand to  directors and he will serve on the compensation committee “we are pleased to announce that paul will join the zoetis board” said zoetis chief executive officer juan ramón alaix “he brings extensive business leadership and global healthcare experience to zoetis along with a deep understanding of the pharmaceutical industry he will be a valuable addition to our board as we continue to grow our position as the world’s leading animal health company” mr bisaro has more than  years of experience in the healthcare industry he is executive chairman of actavis plc a global pharmaceutical company focused on developing manufacturing and commercializing innovative branded pharmaceuticals highquality generic and overthecounter medicines and biologic products he previously served as president ceo and chairman of the board of actavis prior to joining actavis then watson pharmaceuticals he was president and chief operating officer of barr pharmaceuticals inc he also served as general counsel at barr and held various additional roles including senior vice president of strategic business development prior to joining barr mr bisaro was associated with the law firm winston  strawn and a predecessor firm bishop cook purcell and reynolds he also served as a senior consultant with arthur andersen  co about zoetis zoetis zôehtis is the leading animal health company dedicated to supporting its customers and their businesses building on more than  years of experience in animal health zoetis discovers develops manufactures and markets veterinary vaccines and medicines complemented by diagnostic products and genetic tests and supported by a range of services in  the company generated annual revenue of  billion with approximately  employees worldwide at the beginning of  zoetis serves veterinarians livestock producers and people who raise and care for farm and companion animals with sales of its products in  countries for more information visit wwwzoetiscom disclosure notices forwardlooking statements this press release contains forwardlooking statements which reflect the current views of zoetis with respect to business plans or prospects future operating or financial performance expectations regarding products future use of cash and dividend payments and other future events these statements are not guarantees of future performance or actions forwardlooking statements are subject to risks and uncertainties if one or more of these risks or uncertainties materialize or if managements underlying assumptions prove to be incorrect actual results may differ materially from those contemplated by a forwardlooking statement forwardlooking statements speak only as of the date on which they are made zoetis expressly disclaims any obligation to update or revise any forwardlooking statement whether as a result of new information future events or otherwise a further list and description of risks uncertainties and other matters can be found in our annual report on form k for the fiscal year ended december   including in the sections thereof captioned “forwardlooking information and factors that may affect future results” and “item a risk factors” in our quarterly reports on form q and in our current reports on form k these filings and subsequent filings are available online at wwwsecgov wwwzoetiscom or on request from zoetis contact zoetis incmediabill price  owilliampricezoetiscomorelinore white  oelinoreywhitezoetiscomorinvestorsjohn oconnor  ojohnoconnorzoetiscom business wire newshq℠ news on paul m bisaro news home advertising board and executive moves energy health care hedge funds m  a private equity technology person paul m bisaro ▼ topic all topics ▼ organizations find news about organizations alumni find news on alumni of any org industries find news on a particular market your contacts find news on your contacts sign up for free daily alerts on this feed by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions follow change feed paul m bisaro biotech stocks growing faster than other sectors fueled by breakthroughs in rd and clinical trials july    •  pr newswire  version of concerta further demonstrates the capabilities of impaxs rd organization said paul bisaro president and chief executive officer of impax disclaimer marketnewsupdatescom mnu is  impax laboratories receives fda approval for attention deficit hyperactivity disorder treatment july    •  marketline newswire  version of concerta further demonstrates the capabilities of impaxs rd organization said paul bisaro president and ceo of impax we are preparing for launch including  impax announces fda approval of its ab rated generic concerta® methylphenidate hydrochloride extendedrelease tablets cii july    •  pr newswire  version of concerta further demonstrates the capabilities of impaxs rd organization said paul bisaro president and chief executive officer of impax we are preparing for  impax to present at the ubs global healthcare conference may    •  pr newswire  impax laboratories incnasdaq ipxltoday announced that paul bisaro president and chief executive officer will present at the ubs global  impax to present at the bank of america merrill lynch healthcare conference may    •  pr newswire  impax laboratories incnasdaq ipxl today announced that paul bisaro president and chief executive officer and bryan reasons senior vice president  impax reports first quarter  financial results may    •  pr newswire  number of strong performing products and rd opportunities within our portfolio said paul bisaro president and chief executive officer of impax since i joined the  impax announces fda approval and launch of a generic version of vytorin® ezetimibesimvastatin tablets april    •  pr newswire  version of vytorin® and provide patients with an affordable treatment option said paul bisaro president and chief executive officer of impax this launch demonstrates our  impax to present data on rytary® carbidopa and levodopa extendedrelease capsules zomig® zolmitriptan nasal spray and investigational drug ipx at the  american academy of neurology® annual meeting april    •  pr newswire  underscores our commitment to advancing the science for treating neurological disorders said paul bisaro impax president and chief executive officer we see patients cope with  impax announces favorable ruling regarding patent validity for zomig® zolmitriptan nasal spray march    •  pr newswire  decision upholding the validity of the patents for zomig nasal spray said paul bisaro president and ceo of impax we look forward to continuing to  tendon repair and regenerative biomedicine market fastest growing segment in tissue engineering segment march    •  pr newswire  laboratories inc yesterday announced that its board of directors has appointed paul m bisaro as impaxs president and chief executive officer and a member of  dupont impax labs gain giii apparel slides march    •  associated press  inc up  to  the generic drugmaker named former allergan chairman paul bisaro as its new ceo weatherford international plc up  cents to  impax board of directors appoints paul m bisaro president and ceo march    •  pr newswire  laboratories incnasdaq ipxltoday announced that its board of directors has appointed paul m bisaro as impaxs president and chief executive officer and a member of  allergan announces changes to board leadership october    •  marketline newswire  saunders has been elected chairman of the allergans board of directors replacing paul bisaro who served as executive chairman since july   bisaro will  zoetis holds annual meeting of shareholders may    •  business wire  shareholder voting from the meeting are as follows juan ramón alaix paul m bisaro frank a damelio and michael b mccallister have been elected as  pfizer and allergan to combine november    •  business wire  and  current directors of allergan the directors from allergan will be paul bisaro allergans current executive chairman brent saunders allergans current chief executive officer  when us firms decide to desert the country we all pay a price november    •  washington post blogs  as allergan did its desertion deal and became irish thenchief executive paul m bisaro talked about why the companys top executives were not moving to  when us firms decide to desert the country we all pay a price november    •  washington post blogs  as allergan did its desertion deal and became irish thenchief executive paul m bisaro talked about why the companys top executives were not moving to  why allergan is seen as the perfect target hint taxes october    •  moneybeat  allergan plc leerink research analyst jason gerberry also noted that allergan chairman paul bisaro “has overseen massive value creation for shareholders since the company’s days  valeant tells congress a different tax tale than investors july    •  thinkadvisor  on deals with the likes of valeant on a conference call thenceo paul bisaro called his company “handicapped because we’re competing against companies that have  drugmakers like gilead mylan and novonot big pharmaare job creators july    •  fiercepharma  heated pace of ma last year like at actavispushed by both chairman paul bisaro and then by brent saunders who became ceo after actavis bought  allergan to close plant in iceland lay off  june    •  fiercepharma  allergan agn chairman paul bisaro has been quick to cut what he sees as redundant operations  zoetis wont tame pharma ma may    •  the wall street journal  the value of this company” this follows the appointment last month of paul bisaro  former chairman  actavis chairman joins zoetis board under deal with activist investor ackman april    •  fiercepharma  pershing square capital management the new board member is actavis act chairman paul bisaro who helped engineer a takeover of allergana deal that delivered billions  zoetis appoints paul m bisaro to board of directors april    •  business wire   nysezts today announced that its board of directors has appointed paul m bisaro executive chairman of actavis plc to the companys board of directors  actavis ceo brent saunders has a vision for growth march    •  institutional investor  a solid player in generic drugs but after a dinnertime chat between thenpaul bisaroisaro and saunders actavis grew interested in forest labs and its portfolio  related news feeds impax laboratories inc pharmaceuticals board and executive moves in pharmaceuticals alumni of catholic university of america  columbus school of law email linkedin facebook google tweet reddit permalink want to see the full history of news or view news on a particular date upgrade to relsci professional now start my free trial ➤ industry select a topic keyword go  ➤ find an organization select a topic keyword go  ➤ find a person select a topic keyword go  ➤ name of a school or name of an organization select a topic keyword go  ➤ thank you you are now subscribedplease wait for the page to refresh you are now subscribed to this feed you have unsubscribed to this feed thank you you can now subscribe to more relsci news feeds to subscribe to more than one feed please enter a password please confirm your password go  ➤ youve found a premium relsci pro feature follow news on your contacts upgrade to relsci pro now to easily sync your contacts and stay in the know on the news about the people important to you start my free trial ➤ still not convinced check out our full listing of features here not now youve found a premium relsci pro feature search news on keywords curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles start my free trial ➤ still not convinced check out our full listing of features here not now industries find news on a particular market people find news about people organizations find news about organizations alumni find news on alumni of any org your contacts find news on your contacts free daily alerts sign up for free daily alerts on this feed sign up ➤ by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions already have an account click here to login are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ allergan  executive leadership team  allergan homehomeinvestorsinvestorsnewsnewsevents  presentationsevents  presentationsinvestor faqsinvestor faqsanalysts coverageanalysts coveragestock informationstock informationma activitiesma activitiescorporate governancecorporate governanceshareholder servicesshareholder servicesfinancial informationfinancial informationproductsproductswhat we treatwhat we treatkey productskey productsdrug safetydrug safetyqualityqualitypatent noticespatent noticesmedical informationmedical informationr  dr  dwe live open sciencewe live open sciencerd areas of focusrd areas of focusallergan pipelineallergan pipelineclinical trialsclinical trialsaboutaboutcompany profilecompany profileexecutive leadershipexecutive leadershipglobal footprintglobal footprintglobal locationsglobal locationscontactcontactresponsibilityresponsibilitysocial contractsocial contractsocial responsibilitysocial responsibilityallergan foundationallergan foundationcalifornia supply chain disclosurecalifornia supply chain disclosurealliance support and ime grantsalliance support and ime grantshealth care provider partnerships  paymentshealth care provider partnerships  paymentspatient resourcespatient resourcespatient safety  product qualitypatient safety  product qualityphysician resourcesphysician resourcesanimal testinganimal testingnewsnewspress releasespress releasesmedia contactsmedia contactsnewsroomnewsroomcareerscareerscareer opportunitiescareer opportunitiesworking at allerganworking at allerganuniversity recruitinguniversity recruitingveteransveterans home  investors  read the full story allergan acquisition investor information news events  presentations investor faqs analysts coverage stock information stock chart  quote historical price lookup investment calculator ma activities allergan acquisition forest laboratories acquisition warner chilcott acquisition teva agreement corporate governance executive officers and directors committee composition committee charters code of conduct governance guidelines insider transactions allergan compliance program memorandum of association shareholder services information requests investor kit email alerts dividends financial information sec filings annual reports quarterly results proxy materials corporate fact sheet products  what we treat key products our products product prescribing drug safety quality patent notices medical information medical information request r  d  we live open science rd areas of focus allergan pipeline clinical trials participating in an allergan clinical trial clinical trial results sharing post marketing commitments sharing patientlevel data clinical trials investigators investigator initiated trials about  learn more a global growth pharma leader company profile executive leadership global footprint pharmaceuticals business development global locations commercial operations supply chain countries contact responsibility  learn more high priorities sustainability  continual improvement social contract social responsibility environmental employees facilities  manufacturing partners community public policy allergan foundation california supply chain disclosure alliance support and ime grants alliance support independent medical education grants patient resources patient assistance programs patient safety  product quality research and development risks and benefits quality physician resources animal testing news  ceo blog press releases media contacts newsroom allergan images allergan logos company profile executive bios  photos careers  career opportunities working at allergan our employees university recruiting internship  coops fellowship programs veterans go about  executive leadership company profile executive leadership global footprint global locations contact executive leadership driving continued growth success and achievement chairman president and ceo allergan brenton l saunders brent saunders is chairman president and chief executive officer of allergan plc mr saunders has served as a director ceo and president since july  he was elected chairman in  previously he served as chief executive officer and president of forest laboratories and as a director of forest since  mr saunders has significant healthcare industry expertise and a proven trackrecord leading business transformations and integrations prior to forest mr saunders was chief executive officer of bausch  lomb a leading global eye health company serving in this capacity from march  until august  mr saunders also held several leadership positions at scheringplough including the position of president of global consumer health care and was named head of integration for the company’s merger with merck  co and for scheringplough’s acquisition of organon biosciences before joining scheringplough mr saunders was a partner and head of compliance business advisory at pricewaterhousecoopers llp prior to that he was chief risk officer at coventry health care and senior vice president compliance legal and regulatory at home care corporation of america mr saunders began his career as chief compliance officer for the thomas jefferson university health system mr saunders serves on the board of directors of cisco systems and rwjbarnabas health and is a member of the business council and phrma he is also the former chairman of the new york chapter of the american heart association mr saunders earned his mba from temple university school of business his jd from temple university school of law and his bachelor’s degree from the university of pittsburgh evp chief operating officer allergan robert a stewart robert a stewart is the chief operating officer and has served in this role since may  prior to his current appointment mr stewart served as president generics and global operations from march  to may  chief operating officer from july  to march  and president global operations from august  to july  he joined the company then watson in november  as senior vice president global operations mr stewart has  years of experience in global biopharmaceutical leadership with expertise in all aspects of quality manufacturing and supply chain management  before joining watson mr stewart held various positions with abbott laboratories inc from  until  where he most recently served as divisional vice president global supply chain quality assurance and prior to this position served as divisional vice president for uspuerto rico and latin america plant operations preceding his time at abbott laboratories inc he worked for knoll pharmaceutical company from  to  and hoffman laroche inc mr stewart has been a north american manufacturing board member since september  he earned his bachelors degree in business management and finance from fairleigh dickinson university evp  chief commercial officer william meury bill meury is the chief commercial officer and has served in this role since may  mr meury previously served as president branded pharma from march  to may  he joined the company in july  as executive vice president commercial north american brands he has significant experience in launching and commercializing healthcare products prior to joining allergan mr meury served as executive vice president sales and marketing at forest laboratories inc he joined forest in  and held multiple roles of increasing responsibility in marketing new products business development and sales before joining forest mr meury worked in public accounting for reznick fedder  silverman and in financial reporting for mci communications mr meury is currently on the board of directors of several organizations including the jed foundation international council of ophthalmology foundation and the allergan foundation mr meury earned his bachelor’s degree in economics from the university of maryland evp  chief financial officer maria teresa hilado tessa hilado is the chief financial officer and has served in this role since december  ms hilado has  years of global finance experience prior to joining the company ms hilado served as senior vice president finance and treasurer of pepsico inc from  to  before joining pepsico she served as vice president and treasurer for scheringplough corporation from  to  before joining scheringplough ms hilado spent more than  years with general motors corporation in leadership roles of increasing responsibility most notably assistant treasurer from  to  and cfo gmac commercial finance llc from  to  she began her career with far east bank and trust company manila philippines ms hilado currently sits on the board of directors at hb fuller co she earned her bachelor’s degree in management engineering from ateneo de manila university in the philippines and an mba from the university of virginia’s darden school of business administration evp  chief legal officer and corporate secretary a robert d bailey bob bailey is the chief legal officer and corporate secretary and has served in this role since july  previously mr bailey served as senior vice president chief legal officer general counsel and corporate secretary of forest laboratories inc mr bailey previously served from  to  as executive vice president law policy and communications at bausch  lomb and was with the company for more than  years before joining bausch  lomb in  mr bailey was an attorney at nixon peabody formerly nixon hargrave devans  doyle mr bailey is a member of the us chamber litigation board of directors he earned his law degree from the university of minnesota and his undergraduate degree from st olaf college in northfield minnesota evp  chief human resources officer karen l ling esq karen ling is the chief human resources officer and has served in this role since july  she previously served as senior vice president and chief human resources officer for forest laboratories inc from january to july  prior to joining forest ms ling served as senior vice president human resources at merck  co for the company’s global human health and consumer care businesses worldwide beginning in november  previously she served as vice president compensation and benefits at merck and group vice president global compensation  benefits at scheringplough which was acquired by merck prior to joining scheringplough in  ms ling spent  years at wyeth pharmaceuticals in various positions of responsibility in human resources and in wyeth’s labor and employment department before joining wyeth ms ling was an attorney at goldstein and manello pc in boston ms ling is currently a member of the board of directors of the glaucoma foundation inc a nonforprofit organization she earned jd from boston university school of law and a ba from yale university evp  chief rd officer c david nicholson phd david nicholson is the chief rd officer and has served in this role since march  dr nicholson joined the company then actavis as senior vice president global brands rd in august  he has been in research and development in the pharmaceutical industry since  previously he served as chief technology officer and evp rd for bayer cropscience from march  to august  senior vice president of licensing and knowledge management at merck from  to december  and senior vice president responsible for global project management and drug safety at scheringplough from  to  from  to  dr nicholson held various leadership positions at organon where he most recently served as executive vice president rd and was a member of the company’s executive management committee dr nicholson earned his bsc from the university of manchester and his phd from the university of wales evp  chief communications officer alex kelly alex kelly is the evp corporate affairs and chief communications officer and has served in this role since april   previously mr kelly served as senior vice president chief integration officer since july  in this role he led the integration of forest laboratories following its acquisition by actavis he also coled the integration of allergan prior to joining actavis mr kelly was senior vice president chief communications officer public affairs and investor relations at forest laboratories in that role he led forest’s corporate communications and investor relations programs while at forest mr kelly led the integration of aptalis pharma following its acquisition in january  prior to forest mr kelly served as vice president investor relations at bausch  lomb mr kelly was senior vice president investor relations at merck  co inc following the combination with scheringplough where he led the global communications and investor relations team he previously worked for novartis as executive director investor relations after spending  years at pharmacia including ten years in pharmaceutical sales and sales management and four years in investor relations mr kelly currently serves on multiple boards and committees including the california biomedical innovation alliance the allergan foundation and the healthcare institute of new jersey he earned his bachelor of science in pharmacy from purdue university where he graduated cum laude contact allergan us administrative headquarters morris corporate center iii  interpace parkway parsippany nj     country websites global corporate website africa south africa egypt americas argentina barbados bolivia brazil canada chile colombia costa rica dominican republic ecuador el salvador guatemala honduras jamaica mexico panama peru puerto rico trinidad  tobago uruguay venezuela asia pacific australia bahrain bangladesh china hong kong india indonesia israel japan jordan korea kuwait lebanon malaysia new zealand pakistan palestine philippines russia saudi arabia sri lanka singapore taiwan thailand united arab emirates vietnam yemen europe austria belgium bulgaria czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania malta netherlands norway poland portugal romania serbia slovakia spain sweden switzerland turkey ukraine united kingdom paul m bisaro executive profile  biography  bloomberg july    am et pharmaceuticals company overview of impax laboratories inc snapshotpeople  overviewboard memberscommittees executive profile paul m bisaro president ceo  director impax laboratories incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr paul m bisaro serves as an executive chairman of actavis specialty pharmaceuticals co and actavis pharma company mr bisaro has been chief executive officer and president of impax laboratories inc since march   he serves as the executive chairman of allergan pharma co he served as the chief executive officer president chairman and director at actavis limited since october  he served as president and chief operating officer of barr laboratories  inc he served as chief executive officer and president of allergan plc from september   to july  and its chairman of the board from october  to july  he served as the president and chief operating officer of teva branded pharmaceutical products rd inc from december  to august  he joined the barr pharmaceuticals inc in  and served as its general counsel from  to  and served in various additional capacities including senior vice president strategic business development from  to  he served as president and chief operating officer of teva womens health inc until august   mr bisaro has more than  years of experience in the healthcare industry he served as the president and chief operating officer of barr pharmaceuticals inc from  to  he served as the president of duramed and new bli both the subsidiaries of barr pharmaceuticals inc he served as the chief operating officer of new bli prior to joining barr he was associated with the law firm winston  strawn and a predecessor firm bishop cook purcell and reynolds from  to  he also served as a senior consultant with arthur andersen  co he served as member of management board at pliva pharmaceuticals inc since november   and plivalachema as mr bisaro served as an executive chairman of allergan plc formerly known as actavis plc from july   to october   and its executive director from september   until december   he served as the chairman of generic pharmaceutical association since  and  and served as its vice chairman he serves as director of generic pharmaceutical association he has been director of impax laboratories inc since march   he has been an independent director of zoetis inc since may   he has been director of allergan plc formerly known as actavis plc since september   and served as its executive director since september   until december   he serves as an independent director of forsyth capital mortgage corp he served as an independent director of zimmer biomet holdings inc since december   until may   he served as a director of teva branded pharmaceutical products rd inc from june  to  he served as director of barr pharmaceuticals inc from  to  mr bisaro received his undergraduate degree in general studies from the university of michigan in  and juris doctor from catholic university of america in washington dc in read full background corporate headquarters  huntwood avenuehayward california united statesphone fax  board members memberships independent directorforsyth capital mortgage corpdirectorassociation for accessible medicinesexecutive chairmanactavis pharma companyexecutive chairmanallergan pharma copresentdirectorallergan plcpresentdirectoractavis limitedpresentindependent directorzoetis incpresentpresident ceo  directorimpax laboratories inc education bachelors degree university of michiganjd catholic university of america other affiliations allergan plcteva branded pharmaceutical products rd inczimmer biomet holdings incteva womens health incpliva pharmaceuticals incbarr laboratories incforsyth capital mortgage corpuniversity of michigancatholic university of americaassociation for accessible medicinesplivalachema asactavis pharma companyzoetis incactavis limitedallergan pharma co annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationron cohen mdfounder chief executive officer president and directoracorda therapeutics inckarthur joseph higgins ceo president  directordepomed incarthur p bedrosian jdceo  directorlannett company incmhari shanker bhartia btechcochairman and managing directorjubilant life sciences limiteddaniel j abdunnabi chief executive officer president and directoremergent biosolutions inckcompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact impax laboratories inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close paul bisaro for allergan finance llc wpi from the makers of track  manage all of your investments try it now new portfolio       login  sign up search industriestechnologyenergymediafinancegreen issueschinaall conceptsmetalsenergymeatsgrainssoftsetfsindicescurrenciesgeographiesexchangesrateshow to investpersonal financeoptions definitions watson pharmaceuticals wpi     summarybullsbearstopicsdata centralstock chartsec filingsbalanceincomecash flowwpi » topics » paul bisarothese excerpts taken from the wpi k filed feb  paul m bisaro   paul m bisaro age  was appointed president and chief executive officer effective september   prior to joining watson mr bisaro was president and chief operating officer of barr from  to  between  and  mr bisaro served as general counsel and from  to  served in various additional capacities including senior vice president  strategic business development prior to joining barr he was associated with the law firm winston  strawn and a predecessor firm bishop cook purcell and reynolds from  to  mr bisaro also served as a senior consultant with arthur andersen  co mr bisaro received his undergraduate degree in general studies from the university of michigan in  and a juris doctor from catholic university of america in washington dc in    paul m bisaro  paul m bisaro age  was appointed president and chief executive officer effective september   prior to joining watson mr bisaro was president and chief operating officer of barr from  to  between  and  mr bisaro served as general counsel and from  to  served in various additional capacities including senior vice president  strategic business development prior to joining barr he was associated with the law firm winston  strawn and a predecessor firm bishop cook purcell and reynolds from  to  mr bisaro also served as a senior consultant with arthur andersen  co mr bisaro received his undergraduate degree in general studies from the university of michigan in  and a juris doctor from catholic university of america in washington dc in   this excerpt taken from the wpi def a filed apr  paul bisaro   pursuant to his employment agreement mr bisaro was eligible to receive a cash bonus of up to  of his base salary prorated for the portion of the year mr bisaro was employed as our chief executive officer based on our financial performance in  as measured by the adjusted ebitda targets established at the beginning of the year mr bisaros target bonus opportunity was determined following negotiations with mr bisaro which considered among other things the significant impact mr bisaro would have on our ability to meet our targets and his compensation opportunities with his previous employer the committee also considered that the median bonus payment for the most recent fiscal year among our peer group companies was approximately  for chief executive officers as a results of our actual adjusted ebitda results for  exceeding our target for  funding and mr bisaros service from september   to the end of the year the committee determined that a cash incentive of  would be awarded to mr bisaro for performance in    for  the committee approved a bonus program pursuant to which mr bisaro will be eligible to receive a cash bonus of up to  of his then current salary up to  of mr bisaros award will be based upon our financial performance in  as measured by adjusted ebitda and up  of mr bisaros award will be at the discretion of the committee taking into account mr bisaros success in       setting and implementing strategies to develop and grow the our generic brand and distribution business segments  table of contents       implementing our global supply chain cost improvement initiatives including the integration of our offshore operations       improving our quality systems and procedures and       identifying and retaining key executives recruiting key executives and developing succession plans for our senior leaders   the committee may consider other relevant factors in its sole discretion the committee will determine whether and to what extent a bonus will be paid to mr bisaro for fiscal year  after the end of    annual cash incentive awards for our named executive officers     each year the committee adopts a program that provides guidelines pursuant to which it calculates the annual cash incentive awards available to our named executive officers other than our chief executive officer subject to the committees oversight and modification the committee believes that our annual incentive plan provides our named executive officers with a team incentive to both enhance our financial performance and perform at the highest level the terms of these programs are not contained in a formal written plan   under our  cash incentive program each of our named executive officers other than our chief executive officer was eligible to receive an annual cash bonus targeted at a specified percentage of his or her base salary for  these percentages were  for mr russillo  for mr heimers  for mr buchen and  for mr joyce in setting our named executive officers target bonus opportunities the committee considered that the  target total cash compensation levels of messrs russillo heimers buchen and joyce compared to the market th percentile for their positions mr durand who joined us on november   was not eligible for a cash incentive award for our  performance pursuant to the terms of his employment agreement mr durands target bonus level will be not less than  of his base salary   the bonus actually paid to each named executive officer could have ranged from  to  of the named executive officers target bonus depending to varying degrees on i our financial performance in  as measured by adjusted ebitda ii the contribution of the named executive officers business segment to our performance where applicable and iii the evaluation of the named executive officer and his or her department during  as determined by our chief executive officer based on the executives and his departments achievements during  for  the above factors were applied as follows in determining the annual cash incentive award due to each of our named executive officers       for mr heimers fifty percent  of his award was based upon our performance as measured by adjusted ebitda and fifty percent  of his award was based on the adjusted contribution of our brand business segment to our financial results mr heimers received a cash bonus of  which reflected our actual adjusted ebitda of  million adjusted contribution of our brand business segment at the  level and the recommendation of our chief executive officer       for mr russillo fifty percent  of his award was based upon our performance as measured by adjusted ebitda and fifty percent  of his award was based on the adjusted contribution of our generic business segment to our financial results mr russillo received a cash bonus of  which reflected i our actual adjusted ebitda of  million adjusted contribution of our generic business segment at the  level and the recommendation of our chief executive officer and ii an additional bonus equal to  of mr russillos base salary based on his attainment of certain strategic initiatives approved by the committee       for mr buchen sixty percent  of his award was based upon our performance as measured by adjusted ebitda and forty percent  of his award was based on his performance evaluation by our chief executive officer as recommended to the committee mr buchen received a cash bonus of  which reflected our actual adjusted ebitda of  million the recommendation of our chief executive officer and the exercise of the committees discretion  table of contents       for mr joyce sixty percent  of his award was based upon our performance as measured by adjusted ebitda and forty percent  of his award was based on his performance evaluation by our chief executive officer as recommended to the committee mr joyce received a cash bonus of  which reflected our actual adjusted ebitda of  million the recommendation of our chief executive officer and the exercise of the committees discretion   the calculations of the cash incentive awards and the recommendation of our chief executive officer are submitted to the committee for consideration and approval the total amount of cash bonus payable to a named executive officer may be further adjusted by up to twenty five percent  at the discretion of the committee the committee determines whether and to what extent cash incentive awards will be paid for a fiscal year after the end of that fiscal year   these excerpts taken from the wpi k filed feb  paul m bisaro   paul m bisaro age  was appointed president and chief executive officer effective september   prior to joining watson mrbisaro was president and chief operating officer of barr from  to  between  and  mr bisaro served as general counsel and from  to  served in various additional capacities including senior vice president  strategic business development prior to joining barr he was associated with the law firm winston  strawn and a predecessor firm bishop cook purcell and reynolds from  to  mr bisaro also served as a senior consultant with arthur andersen  co mr bisaro received his undergraduate degree in general studies from the university of michigan in  and a juris doctor from catholic university of america in washington dc in    paul m bisaro  paul m bisaro age  was appointed president and chief executive officer effective september   prior to joining watson mrbisaro was president and chief operating officer of barr from  to  between  and  mr bisaro served as general counsel and from  to  served in various additional capacities including senior vice president  strategic business development prior to joining barr he was associated with the law firm winston  strawn and a predecessor firm bishop cook purcell and reynolds from  to  mr bisaro also served as a senior consultant with arthur andersen  co mr bisaro received his undergraduate degree in general studies from the university of michigan in  and a juris doctor from catholic university of america in washington dc in   excerpts on this pagek  sectionsfeb  def aapr  k  sectionsfeb  related topics for wpiedward heimersexecutive officers registrantsign bonusallen chaoview morepaul bisaro elsewhere barr pharmaceuticals brl skip the spreadsheet track your investments automatically start now wikinvest         use of this site is subject to express terms of service privacy policy and disclaimer by continuing past this page you agree to abide by these terms any information provided by wikinvest including but not limited to company data competitors business analysis market share sales revenues and other operating metrics earnings call analysis conference call transcripts industry information or price targets should not be construed as research trading tips or recommendations or investment advice and is provided with no warrants as to its accuracy stock market data including us and international equity symbols stock quotes share prices earnings ratios and other fundamental data is provided by data partners stock market quotes delayed at least  minutes for nasdaq  mins for nyse and amex market data by xignite see data providers for more details company names products services and branding cited herein may be trademarks or registered trademarks of their respective owners the use of trademarks or service marks of another is not a representation that the other is affiliated with sponsors is sponsored by endorses or is endorsed by wikinvest about  blog  press  feedback  help  get involvedmobile  advertise  licensing  partnerships  blogger tools  jobs